data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

ORIC Pharmaceuticals

(NASDAQ:ORIC)

Intraday

$8.07

0.40[5.22%]

After-Hours

$8.07

0[0.00%]

Perks Buy Compare Brokers

$8.07

0.40[5.22%]

At close: Apr 26

$8.07

0[0.00%]

After Hours: 4:20PM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for ORIC Pharmaceuticals Stock (NASDAQ:ORIC)

ORIC Pharmaceuticals Stock (NASDAQ: ORIC)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, April 19, 2024

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Chris Katje - Apr 19, 2024, 12:28PM

Monday, April 15, 2024

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts In Phase 1b Trial Of ORIC-114 In Patients With Mutated NSCLC
Benzinga Newsdesk - Apr 15, 2024, 4:16PM

Monday, April 08, 2024

ORIC Pharmaceuticals Presents Preclinical Data On Two Programs At The 2024 AACR Annual Meeting
Benzinga Newsdesk - Apr 8, 2024, 8:15AM

Wednesday, March 27, 2024

JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $18
Benzinga Newsdesk - Mar 27, 2024, 10:40AM

Thursday, March 21, 2024

Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor - Mar 21, 2024, 9:15AM
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $21
Benzinga Newsdesk - Mar 21, 2024, 6:15AM

Tuesday, March 12, 2024

These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results
Avi Kapoor - Mar 12, 2024, 12:55PM
Oppenheimer Maintains Outperform on ORIC Pharmaceuticals, Raises Price Target to $17
Benzinga Newsdesk - Mar 12, 2024, 12:49PM
Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target
Benzinga Newsdesk - Mar 12, 2024, 8:22AM
Baird Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $25
Benzinga Newsdesk - Mar 12, 2024, 8:06AM

Monday, March 11, 2024

ORIC Pharmaceuticals Q4 EPS $(0.49), Inline
Happy Mohamed - Mar 11, 2024, 4:22PM

Friday, March 01, 2024

Wedbush Maintains Outperform on ORIC Pharmaceuticals, Raises Price Target to $20
Benzinga Newsdesk - Mar 1, 2024, 8:43AM

Thursday, February 29, 2024

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor - Feb 29, 2024, 2:00PM
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
Avi Kapoor - Feb 29, 2024, 11:30AM

Friday, February 23, 2024

Cantor Fitzgerald Initiates Coverage On ORIC Pharmaceuticals with Overweight Rating
Benzinga Newsdesk - Feb 23, 2024, 1:42PM

Monday, January 22, 2024

ORIC Pharmaceuticals Announces $125M Private Placement Of ~12.5M Shares At $10.00/Share
Benzinga Newsdesk - Jan 22, 2024, 8:34AM

Monday, January 08, 2024

ORIC Announces Initial Phase 1b Data For ORIC-944; Says Demonstrated 'potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination development'
Benzinga Newsdesk - Jan 8, 2024, 8:44AM

Friday, December 15, 2023

Oric Pharmaceuticals Inc Files For Shelf Of Up To 12.1M Shares Of Common Stock By Selling Stockholders
Benzinga Newsdesk - Dec 15, 2023, 4:35PM

Wednesday, December 13, 2023

Where ORIC Pharmaceuticals Stands With Analysts
Benzinga Insights - Dec 13, 2023, 12:00PM
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $15
Benzinga Newsdesk - Dec 13, 2023, 6:28AM

Monday, December 11, 2023

Initial Phase 1 Dose Escalation Data For ORIC-533 In Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity And Strong Safety Profile Supporting Potential For Combination Development At The 65th American Society Of Hematology Annual Meeting
Benzinga Newsdesk - Dec 11, 2023, 12:05PM

Monday, November 06, 2023

ORIC Pharmaceuticals Q3 EPS $(0.44) Beats $(0.46) Estimate
Benzinga Newsdesk - Nov 6, 2023, 5:45PM

Thursday, November 02, 2023

ORIC Pharmaceuticals To Present Initial Phase 1b Clinical Data For ORIC-533 In Multiple Myeloma At The 65th American Society Of Hematology Annual Meeting
Benzinga Newsdesk - Nov 2, 2023, 9:12AM

Thursday, October 26, 2023

Meta To Rally Over 42%? Here Are 10 Top Analyst Forecasts For Thursday
Lisa Levin - Oct 26, 2023, 7:53AM
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $16
Benzinga Newsdesk - Oct 26, 2023, 6:42AM

Monday, October 23, 2023

Analyst Expectations for ORIC Pharmaceuticals's Future
Benzinga Insights - Oct 23, 2023, 10:00AM
Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $14 Price Target
Benzinga Newsdesk - Oct 23, 2023, 9:09AM

Saturday, October 21, 2023

ORIC Pharmaceuticals Announced Initial Phase 1 Dose Escalation Data Of ORIC-114 In Patients With EGFR And HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
Charles Gross - Oct 21, 2023, 9:28AM

Tuesday, October 17, 2023

ORIC Pharmaceuticals To Present Initial Phase 1b Clinical Data For ORIC 114 In EGFR/HER2 Exon 20 Mutated NSCLC At The European Society Of Medical Oncology Congress 2023
Benzinga Newsdesk - Oct 17, 2023, 4:30PM

Friday, September 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
Benzinga Insights - Sep 22, 2023, 11:00AM
Wedbush Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $14
Benzinga Newsdesk - Sep 22, 2023, 4:27AM

Wednesday, August 16, 2023

Baird Maintains Outperform on ORIC Pharmaceuticals, Raises Price Target to $27
Benzinga Newsdesk - Aug 16, 2023, 8:05AM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Aug 15, 2023, 7:10AM

Monday, August 14, 2023

Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Aug 14, 2023, 12:49PM

Friday, August 11, 2023

Oric Pharmaceuticals shares are trading higher after the company reported a year-over-year increase in Q2 EPS results.
Benzinga Newsdesk - Aug 11, 2023, 3:43PM

Thursday, August 10, 2023

ORIC Pharmaceuticals Q2 EPS $(0.50) Up From $(0.51) YoY
Benzinga Newsdesk - Aug 10, 2023, 5:21PM

Wednesday, July 12, 2023

Stocks Pulsate As June Inflation Undercuts Expectations: 10 Major Reactions
AJ Fabino - Jul 12, 2023, 10:26AM

Thursday, June 29, 2023

ORIC Pharmaceuticals President and CEO Trades $160K In Company Stock
Benzinga Insights - Jun 29, 2023, 11:05AM

Monday, June 26, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jun 26, 2023, 1:37PM
Why Oric Pharmaceuticals Stock Is Shooting Higher Today
Nabaparna Bhattacharya - Jun 26, 2023, 12:34PM
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jun 26, 2023, 12:31PM
Oric Pharmaceuticals shares are trading higher after the company announced $85 million in private placement financing.
Benzinga Newsdesk - Jun 26, 2023, 10:19AM
Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday
Lisa Levin - Jun 26, 2023, 10:13AM
ORIC Pharmaceuticals Announces $85M Private Placement Financing
Happy Mohamed - Jun 26, 2023, 8:44AM

Thursday, June 08, 2023

HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $14 Price Target
Benzinga Newsdesk - Jun 8, 2023, 9:10AM

Wednesday, May 10, 2023

HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $14
Benzinga Newsdesk - May 10, 2023, 6:15AM

Monday, May 08, 2023

ORIC Pharmaceuticals Q1 EPS $(0.53) Beats $(0.54) Estimate
Michael Horton - May 8, 2023, 4:26PM

Tuesday, April 18, 2023

ORIC Pharmaceuticals Presents Preclinical Data On Two Programs At The 2023 American Association For Cancer Research Annual Meeting
Happy Mohamed - Apr 18, 2023, 4:27PM

Wednesday, April 05, 2023

Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $8
Benzinga Newsdesk - Apr 5, 2023, 7:15AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved